Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 6/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16899794 | 1.00 | PRCP (0.34) | PRCPKCNH2CNR1IRAK4LRRK2 | |
| SCHEMBL16907851 | 1.00 | PRCP (0.34) | PRCPKCNH2CNR1IRAK4LRRK2 | |
| SCHEMBL16899704 | 1.00 | PRCP (0.34) | PRCPKCNH2CNR1IRAK4LRRK2 | |
| SCHEMBL16899702 | 1.00 | PRCP (0.34) | PRCPKCNH2CNR1IRAK4LRRK2 | |
| SCHEMBL16899705 | 1.00 | PRCP (0.34) | PRCPKCNH2CNR1IRAK4LRRK2 | |
| SCHEMBL16899774 | 0.81 | KDM5A (0.34) | KDM5AHRH3 | |
| SCHEMBL16899746 | 0.80 | IRAK4 (0.37) | IRAK4KDM5AWDR5 | |
| SCHEMBL16899745 | 0.80 | IRAK4 (0.37) | IRAK4KDM5AWDR5 | |
| SCHEMBL16899749 | 0.80 | IRAK4 (0.37) | IRAK4KDM5AWDR5 | |
| SCHEMBL16907864 | 0.80 | IRAK4 (0.37) | IRAK4KDM5AWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10314841-B2 | Substituted pyrazoles as IRAK inhibitors | MERCK PATENT GMBH (DE) | 2019-06-11 | — | — | US | disclosed |
| US-20180169094-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | MERCK PATENT GMBH (DE) | 2018-06-21 | — | — | US | disclosed |
| US-20180169094-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | MERCK PATENT GMBH (DE) | 2018-06-21 | — | — | US | disclosed |
| EP-3092225-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | Merck Patent GmbH (DE) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015106058-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | MERCK PATENT GMBH (DE) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169094-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | IRAK2, IRAK3, IRAK1 | PRCP 3445/4885KCNH2 4442/4885CNR1 3932/4885 |
| US-10314841-B2 | Substituted pyrazoles as IRAK inhibitors | IRAK2, IRAK3, IRAK1 | PRCP 3432/4885KCNH2 3949/4885CNR1 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.